Analysts Offer Predictions for Humana Inc’s FY2019 Earnings (HUM)

Humana Inc (NYSE:HUM) – Stock analysts at Cantor Fitzgerald issued their FY2019 EPS estimates for shares of Humana in a research note issued on Thursday. Cantor Fitzgerald analyst S. Halper expects that the insurance provider will earn $16.60 per share for the year. Cantor Fitzgerald has a “Hold” rating and a $250.00 price target on the stock.

Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. reissued a “hold” rating and issued a $271.00 target price (up from $253.00) on shares of Humana in a research report on Monday. ValuEngine downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Credit Suisse Group began coverage on shares of Humana in a research report on Thursday, November 2nd. They set a “neutral” rating and a $256.00 price objective on the stock. Zacks Investment Research downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, Oppenheimer boosted their price objective on shares of Humana from $275.00 to $305.00 and gave the company an “outperform” rating in a research report on Thursday. Eight investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Humana currently has a consensus rating of “Buy” and a consensus price target of $270.63.

Humana (NYSE:HUM) opened at $265.32 on Monday. The firm has a market cap of $36,528.92, a P/E ratio of 15.91, a PEG ratio of 1.44 and a beta of 0.93. The company has a quick ratio of 1.61, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. Humana has a 1 year low of $203.36 and a 1 year high of $293.35.

Humana (NYSE:HUM) last released its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.06. The business had revenue of $13.19 billion for the quarter, compared to the consensus estimate of $13.14 billion. Humana had a net margin of 4.55% and a return on equity of 16.13%. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period last year, the firm posted $2.34 earnings per share.

A number of hedge funds have recently bought and sold shares of HUM. Shelton Capital Management bought a new stake in Humana in the second quarter worth approximately $287,000. Bank of Nova Scotia lifted its stake in shares of Humana by 838.2% in the second quarter. Bank of Nova Scotia now owns 32,632 shares of the insurance provider’s stock worth $7,852,000 after buying an additional 29,154 shares during the last quarter. Scotia Capital Inc. lifted its stake in shares of Humana by 4.8% in the second quarter. Scotia Capital Inc. now owns 2,200 shares of the insurance provider’s stock worth $529,000 after buying an additional 100 shares during the last quarter. Sterling Capital Management LLC acquired a new stake in shares of Humana in the second quarter worth $253,000. Finally, Koch Industries Inc. acquired a new stake in shares of Humana in the second quarter worth $404,000. 94.13% of the stock is owned by institutional investors.

In other Humana news, VP Timothy S. Huval sold 1,382 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the completion of the sale, the vice president now directly owns 11,557 shares of the company’s stock, valued at $2,843,484.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total transaction of $412,983.63. Following the completion of the sale, the senior vice president now directly owns 9,888 shares of the company’s stock, valued at $2,432,151.36. The disclosure for this sale can be found here. Insiders sold 10,115 shares of company stock valued at $2,501,627 over the last three months. Insiders own 0.80% of the company’s stock.

Humana announced that its Board of Directors has authorized a share buyback program on Thursday, December 14th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the insurance provider to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.75%. This is an increase from Humana’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend is Wednesday, March 28th. Humana’s payout ratio is currently 9.59%.

TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/analysts-offer-predictions-for-humana-incs-fy2019-earnings-hum.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply